Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6761 - 6768 of 12140 results
Making the Sausage: Lower Courts Grapple With the Supreme Court’s TC Heartland Venue Decision
September 27, 2017| Blog| Viewpoint
“In Light of the Specification”: Federal Circuit Weighs in on the Broadest Reasonable Interpretation
September 27, 2017| Blog| Viewpoint
Building a Health App? Part Two: Protecting Your Intellectual Property
September 26, 2017| Blog| Viewpoint
Latest Travel Restrictions from Trump Administration
September 26, 2017| Alert| Viewpoint
Book Review: Privacy in the Workplace
September 26, 2017| News
Fractal Geometry, Actuarial Risk, and §1332 Waivers—The Role of the States in Reforming Health Care
September 25, 2017| Blog| Viewpoint
Building a Health App? Part 2: Protecting Your Intellectual Property
September 25, 2017| Blog| Viewpoint
DTSA Does Not Create a Private Civil Cause of Action for Conspiracy to Commit Trade Secret Theft
September 25, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Events
Podcasts
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|